JAZZ250117C60000
- 0.00
- 0.000.00%
Jazz Pharmaceuticals Newsroom
JP Morgan 2025: Jazz Pharmaceuticals Focusing on Oncology Pipeline
Jazz Pharmaceuticals Plc (JAZZ): Analysts Recommend This 52-Week High Stocks Now
Express News | Jazz Pharmaceuticals PLC - Expects to Meet 2024 Revenue Guidance
RBC Capital Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
Zymeworks Says It Has Enough Cash to Operate Through H2 2027
Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) Delivered A Weaker ROE Than Its Industry
Jefferies Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $170
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), Natera (NTRA) and Neumora Therapeutics, Inc. (NMRA)
Executive Reshuffles: BA, EXPE, TPVG and GEO
Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Needham Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Cuts Target Price to $195
TD Cowen Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $195
Jazz Pharmaceuticals (JAZZ) Gets a Buy From TD Cowen
Jazz Pharmaceuticals Announces CEO Succession Plan; Bruce Cozadd, Co-Founder, Chairperson And CEO, Plans To Retire As CEO Upon Appointment Of Successor By The End Of 2025; Will Continue As Chair Of The Board; Jazz Remains On Track To Meet Its FY24...
Express News | Jazz Pharmaceuticals PLC: Bruce Cozadd Will Continue as Chair of Board
Express News | Jazz Pharmaceuticals Outlook FY Revenue USD 4,000-4,100 Million
Express News | Jazz Pharmaceuticals Announces CEO Succession Plan
Press Release: Jazz Pharmaceuticals Announces CEO Succession Plan
Sentiment Still Eluding Jazz Pharmaceuticals Plc (NASDAQ:JAZZ)
Analysts Conflicted on These Healthcare Names: Jazz Pharmaceuticals (JAZZ), Acadia Healthcare (ACHC) and Genmab (GMAB)